A5101614218- Hepatocellular Carcinoma Treatment and Prognosis
- Cancer Immunotherapy and Biomarkers
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Liver Disease Diagnosis and Treatment
- Hepatitis B Virus Studies
- Radiomics and Machine Learning in Medical Imaging
- Ferroptosis and cancer prognosis
- Liver physiology and pathology
- Pancreatic and Hepatic Oncology Research
- Cancer, Lipids, and Metabolism
- Cancer Genomics and Diagnostics
- Immunotherapy and Immune Responses
- MRI in cancer diagnosis
- Cancer Mechanisms and Therapy
- Liver Disease and Transplantation
- Multiple and Secondary Primary Cancers
- Cancer Research and Treatments
- Lung Cancer Diagnosis and Treatment
- AI in cancer detection
- Lung Cancer Treatments and Mutations
- Renal cell carcinoma treatment
- Bladder and Urothelial Cancer Treatments
- Cancer-related molecular mechanisms research
- Thyroid Cancer Diagnosis and Treatment
- Immune cells in cancer
Sun Yat-sen University
2018-2025
The First Affiliated Hospital, Sun Yat-sen University
2018-2025
Institute of Precision Mechanics
2022
BackgroundHepatocellular carcinoma (HCC) often presents with multiple nodules within the liver, limited effective interventions. The high genetic heterogeneity of HCC might be major cause treatment failure. We aimed to characterize genomic heterogeneity, infer clonal evolution, investigate RNA expression pattern and explore tumour immune microenvironment profile multifocal HCC.Patients methodsWhole-exome sequencing were carried out in 34 tumours 6 adjacent normal liver tissue samples from...
Radiotherapy is an increasingly essential therapeutic strategy in the management of hepatocellular carcinoma (HCC). Nevertheless, resistance to radiotherapy one primary obstacles successful treatment outcomes. Hence, we aim elucidate mechanisms underlying radioresistance and identify reliable biotargets that would be inhibited enhance efficacy HCC.From a label-free quantitative proteome screening, identified transfer RNA (tRNA; guanine- N [7]-) methyltransferase 1 (METTL1), key enzyme for...
Background The evidence of combining sorafenib with transarterial chemoembolization (TACE) for intermediate-stage recurrent hepatocellular carcinoma (HCC) is limited. Patient responses to this treatment varied because the heterogeneous nature HCC, making it important identify patients who are most likely benefit from combination therapy. Purpose To compare administered in TACE versus alone HCC after initial hepatectomy and determine relationship microvascular invasion (MVI) survival....
Abstract Background Limited effective intervention for advanced hepatocellular carcinoma (HCC) is available. This study aimed to investigate the potential clinical utility of apatinib, a highly selective inhibitor vascular endothelial growth factor receptor-2 (VEGFR2) tyrosine kinase, as radiosensitizer in treatment HCC. Methods Four human HCC cell lines SMMC-7721, MHCC-97H, HCCLM3 and Hep-3B were treated with irradiation or combination treatment. Colony formation assay, flow cytometry...
To investigate the phenotypic heterogeneity of tissue-resident synovial fibroblasts and their role in inflammatory response rheumatoid arthritis (RA). We used single-cell spatial transcriptomics to profile cells gene expressions tissues identify changes patients with osteoarthritis, RA sustained remission active state. Immunohistology, multiplex immunofluorescence flow cytometry were subsets. Deconvolution methods further validated our findings two cohorts (PEAC R4RA) treatment response....
ABSTRACT Background and Aim Intrahepatic cholangiocarcinoma (ICC) is the second most common primary liver cancer whose incidence increasing globally. However, high tumor heterogeneity of ICC restricts efficacy available systematic therapies. We aim to dissect utilizing high‐resolution single‐cell RNA sequencing identify novel therapeutic targets. Methods performed (scRNA‐seq) 26 samples from 23 patients spatial transcriptomic six sections patients. Bulk RNA‐seq data two public datasets were...
517 Background: The persistent challenge of elevated re-recurrence rates following secondary hepatectomy complicates the prospects for improving survival in recurrent hepatocellular carcinoma (rHCC) patients. Immunotherapy combined with targeted drugs have been first-line therapy advanced HCC and shown good response rate neoadjuvant situation. However, effectiveness safety combination treatment has not reported rHCC To address this, we conducted present phase 2 clinical trial treatments...
To compare the efficacy of low dose (27 mg) Bacillus Calmette-Guérin (BCG) and a full (81 BCG immunotherapy for patients with intermediate high-risk non-muscle invasive bladder cancer (NMIBC) after typical transurethral resection. We constructed Markov model 20-year simulation disease to overall survival NMIBC between full-dose therapy (FD group) low-dose (LD group). Base case analysis, one-way two-way sensitivity analysis second-order Monte Carlo were performed based on data from 15...
Previous studies demonstrated a promising prognosis in advanced hepatocellular carcinoma (HCC) patients who underwent surgery, yet consensus of which population would benefit most from surgery is still unreached. A total 496 HCC initially liver resection were consecutively collected. Least absolute shrinkage and selection operator (LASSO) regression was performed to select significant pre-operative factors for recurrence-free survival (RFS). prognostic score constructed these used divide...
Pathological MVI diagnosis could help to determine the prognosis and need for adjuvant therapy in hepatocellular carcinoma (HCC). However, narrative reporting (NR) would miss relevant clinical information non-standardized sampling underestimate detection. Our objective was explore impact of innovative synoptic (SR) seven-point (SPRING) protocol on microvascular invasion (MVI) rate patient outcomes. In retrospective cohort, we extracted status from NR three centers re-reviewed specimen...
e16267 Background: Prognoses of patients with hepatocellular carcinoma (HCC) remain unsatisfactory due to the high recurrence rate after curative hepatectomy. In this study, we investigated safety and efficacy neoadjuvant Cadonilimab (PD-1/CTLA-4, a bi-specific antibody) in combination transarterial chemoembolization(TACE) for risk. Methods: For phase II, single-centre, single-arm trial, resectable HCC (BCLC stage A/B) participants were enrolled, who should meet at least one following...
e15657 Background: Microvascular invasion (MVI) is an important risk factor of recurrence for hepatocellular carcinoma (HCC). We aimed to explore the relationship number sampling sites (NuSS) and location with positive rate MVI, investigate cut-off values NuSS. Methods: From May 2010 Feb 2017, 910 HCC patients undergone hepatectomy well-preserved tissue blocks were retrospectively enrolled. Associations between NuSS rates MVI investigated. The thresholds according different factors...
Background: Pretreatment evaluation of tumor biology and microenvironment hepatocellular carcinoma (HCC) are important to predict prognosis plan treatment. We aimed develop nomograms based on Gd-EOB-DTPA-enhanced magnetic resonance imaging (MRI) microvascular invasion (MVI), differentiation, immunoscore. Methods: This retrospective study included 273 patients with HCC who underwent preoperative MRI. Patients were assigned two groups: training (N = 191) validation 82). Univariable...
With prevalence of hepatocellular carcinoma (HCC) in low-risk population (LRP), establishing a non-invasive diagnostic strategy becomes increasingly urgent to spare unnecessary biopsies this population. The purposes study were find characterisics HCC and establish proper method diagnose LRP.A total 681 patients LRP (defined as the without cirrhosis, chronic HBV infection or history) collected from 2 institutions. images computed tomography (CT) magnetic resonance imaging (MRI) manually...